Trial Profile
A Phase I Clinical Trial of the Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Narazaciclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms HanX trial
- Sponsors HanX Biopharmaceuticals
- 02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 21 Sep 2023 Planned primary completion date changed from 4 Apr 2023 to 30 Dec 2023.
- 07 Feb 2023 Status changed from recruiting to active, no longer recruiting.